Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  ALK-Abello A/S    ALK B   DK0060027142

ALK-ABELLO A/S (ALK B)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
1124(c) 1162(c) 1162(c) 1186(c) 1168(c) Last
23 703 12 844 17 692 21 401 23 521 Volume
+2.74% +3.38% 0.00% +2.07% -1.52% Change
More quotes
Financials (DKK)
Sales 2018 2 771 M
EBIT 2018 -167 M
Net income 2018 -232 M
Debt 2018 561 M
Yield 2018 -
Sales 2019 3 028 M
EBIT 2019 -114 M
Net income 2019 -133 M
Debt 2019 872 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 4,47x
EV / Sales2019 4,20x
Capitalization 11 830 M
More Financials
Company
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies.It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings.Its treatment comprises allergy vaccines, emergency treatment, and allergy... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of ALK-Abello A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ALK-ABELLO A/S
05/27ALLERGY EXPERTS : "Clinical effect of ALK's tree SLIT-tablet among the most sign..
PU
05/10In Europe, Mylan's rivals try to plug EpiPen shortages
RE
05/04ALK ABELLO A/S : Three-month interim report (Q1) 2018
AQ
05/01ALK-ABELLO A/S : quaterly earnings release
05/01ALK ABELLO A/S : Release date of three-month interim report (Q1) 2018 and audio ..
AQ
04/17ALK ABELLO A/S : partner for Japan, Torii, secures pricing for new Japanese ceda..
AQ
04/11ALK ABELLO A/S : announces allergy diagnostic partnership with Rellergen in Chin..
AQ
03/20ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
AQ
03/20ALK ABELLO A/S : Grant of share options and performance shares to members of the..
AQ
03/16ALK ABELLO A/S : Articles of Association
AQ
More news
Sector news : Pharmaceuticals - NEC
07/13INDIVIOR : wins preliminary injunction against generic rival
RE
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
07/13NOVARTIS : Played Down Ties to Trump Lawyer Michael Cohen, Report Says
DJ
07/13JOHNSON & JOHNSON : J&J vows to overturn $4.7 billion talc verdict but experts s..
RE
07/13NOVARTIS : disputes U.S. senators' report on Cohen contract
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
05/04$ALKb -Abello ALK-Abello (Buy, TP: DKK1000.00) - Good start to new strategy: .. 
05/04$ALKb -Abello ALK-Abello (Buy, TP: DKK950.00) - Q1 beat, strong start to the .. 
02/16ALK Abello A/S : partner, Torii, gains paediatric approval for the house dust.. 
01/30ALK Abello A/S : Release date of annual report 2017 and audio cast  
2017ALK Abello A/S : — Financial calendar for the 2018 financial year  
More tweets
Qtime:18
News from SeekingAlpha
2017Alk Abello AS (AKBLF) - Investor Presentation - Slideshow 
2017Pricing set in France for ALK's dust-mite allergy pill Acarizax 
2017Alk Abello AS ADR 2017 Q3 - Results - Earnings Call Slides 
2017ALK accelerates commercial launch of dust mite tablet in North America to Q4;.. 
2017ALK-ABELLO AS B SHS 2017 Q2 - Results - Earnings Call Slides 
Chart ALK-ABELLO A/S
Duration : Period :
ALK-Abello A/S Technical Analysis Chart | ALK B | DK0060027142 | 4-Traders
Technical analysis trends ALK-ABELLO A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 935  DKK
Spread / Average Target -20%
EPS Revisions
Managers
NameTitle
Carsten Hellmann President & Chief Executive Officer
Steen Riisgaard Chairman
Søren Daniel Niegel Executive Vice President-Operations
Soren Jelert Chief Financial Officer & Executive Vice President
Henrik Hugo Jacobi Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLO A/S57.84%1 855
JOHNSON & JOHNSON-8.56%337 763
PFIZER3.59%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193